Integra Lifesciences Holdings EBITDA Margin Growth & History (IART)
Integra Lifesciences Holdings's ebitda margin was −26.52% for fiscal 2025.
View full Integra Lifesciences Holdings company overviewIntegra Lifesciences Holdings annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −26.52% | −32.24 pp |
| 2024 | 2024-12-31 | 5.72% | −4.97 pp |
| 2023 | 2023-12-31 | 10.69% | −8.11 pp |
| 2022 | 2022-12-31 | 18.80% | +2.37 pp |
| 2021 | 2021-12-31 | 16.44% | +0.31 pp |
| 2020 | 2020-12-31 | 16.13% | +2.73 pp |
| 2019 | 2019-12-31 | 13.39% | −1.67 pp |
| 2018 | 2018-12-31 | 15.06% | +3.80 pp |
| 2017 | 2017-12-31 | 11.26% | −7.69 pp |
| 2016 | 2016-12-31 | 18.95% | +3.27 pp |
| 2015 | 2015-12-31 | 15.68% | +1.34 pp |
| 2014 | 2014-12-31 | 14.35% | +4.82 pp |
| 2013 | 2013-12-31 | 9.53% | −5.69 pp |
| 2012 | 2012-12-31 | 15.21% | +1.74 pp |
| 2011 | 2011-12-31 | 13.47% | −5.36 pp |
| 2010 | 2010-12-31 | 18.83% | −1.32 pp |
| 2009 | 2009-12-31 | 20.15% | +8.21 pp |
| 2008 | 2008-12-31 | 11.94% | — |
Integra Lifesciences Holdings quarterly ebitda margin
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 15.73% | +129.35 pp |
| Q1 2026 | 2026-03-31 | 14.92% | — |
| Q4 2025 | 2025-12-31 | 15.27% | — |
| Q3 2025 | 2025-09-30 | 13.54% | — |
| Q2 2025 | 2025-06-30 | −113.62% | — |
| Q2 2020 | 2020-06-30 | 16.92% | −2.07 pp |
| Q1 2020 | 2020-03-31 | 15.88% | −0.64 pp |
| Q4 2019 | 2019-12-31 | 16.19% | +0.07 pp |
| Q3 2019 | 2019-09-30 | 1.85% | −12.56 pp |
| Q2 2019 | 2019-06-30 | 18.99% | +4.10 pp |
| Q1 2019 | 2019-03-31 | 16.51% | +1.76 pp |
| Q4 2018 | 2018-12-31 | 16.12% | +6.93 pp |
| Q3 2018 | 2018-09-30 | 14.41% | +3.08 pp |
| Q2 2018 | 2018-06-30 | 14.89% | +1.22 pp |
| Q1 2018 | 2018-03-31 | 14.75% | +3.28 pp |
| Q4 2017 | 2017-12-31 | 9.19% | −13.92 pp |
| Q3 2017 | 2017-09-30 | 11.34% | −7.91 pp |
| Q2 2017 | 2017-06-30 | 13.67% | −2.53 pp |
| Q1 2017 | 2017-03-31 | 11.47% | −5.57 pp |
| Q4 2016 | 2016-12-31 | 23.11% | +5.58 pp |
| Q3 2016 | 2016-09-30 | 19.25% | +7.66 pp |
| Q2 2016 | 2016-06-30 | 16.20% | −1.15 pp |
| Q1 2016 | 2016-03-31 | 17.04% | +0.73 pp |
| Q4 2015 | 2015-12-31 | 17.53% | −1.65 pp |
| Q3 2015 | 2015-09-30 | 11.59% | +0.46 pp |
| Q2 2015 | 2015-06-30 | 17.35% | +5.43 pp |
| Q1 2015 | 2015-03-31 | 16.31% | +5.76 pp |
| Q4 2014 | 2014-12-31 | 19.18% | −7.31 pp |
| Q3 2014 | 2014-09-30 | 11.13% | +20.26 pp |
| Q2 2014 | 2014-06-30 | 11.93% | +3.08 pp |
| Q1 2014 | 2014-03-31 | 10.55% | +5.88 pp |
| Q4 2013 | 2013-12-31 | 26.48% | +11.54 pp |
| Q3 2013 | 2013-09-30 | −9.13% | −24.86 pp |
| Q2 2013 | 2013-06-30 | 8.85% | −6.02 pp |
| Q1 2013 | 2013-03-31 | 4.68% | −10.64 pp |
| Q4 2012 | 2012-12-31 | 14.95% | +4.81 pp |
| Q3 2012 | 2012-09-30 | 15.73% | +0.33 pp |
| Q2 2012 | 2012-06-30 | 14.87% | +3.24 pp |
| Q1 2012 | 2012-03-31 | 15.31% | −1.72 pp |
| Q4 2011 | 2011-12-31 | 10.13% | −7.73 pp |
| Q3 2011 | 2011-09-30 | 15.40% | −4.43 pp |
| Q2 2011 | 2011-06-30 | 11.63% | −7.46 pp |
| Q1 2011 | 2011-03-31 | 17.03% | −1.54 pp |
| Q4 2010 | 2010-12-31 | 17.86% | — |
| Q3 2010 | 2010-09-30 | 19.84% | +0.22 pp |
| Q2 2010 | 2010-06-30 | 19.09% | — |
| Q1 2010 | 2010-03-31 | 18.57% | — |
| Q3 2009 | 2009-09-30 | 19.61% | — |
Integra Lifesciences Holdings ebitda margin trends
Over the last five fiscal years, Integra Lifesciences Holdings's ebitda margin decreased from 16.13% to −26.52%, a change of −42.64 percentage points. The latest reported quarter, Q2 2026, shows 15.73%.
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Integra Lifesciences Holdings source filings ↗